A little-known veterinary sedative is rapidly contaminating illegal fentanyl supplies across the United States, creating a public health crisis that standard overdose treatments cannot fully address. Medetomidine, a sedative licensed for use in dogs, has emerged as the newest threat to people who use opioids, replacing xylazine as enforcement efforts disrupted that drug's supply chain. Between 2023 and 2024, law enforcement drug seizures detected medetomidine 247 times in 2023, then jumped to 2,616 cases in 2024, a rise of 950 percent. By 2025, detections reached 8,233 cases, a further 215 percent increase year-over-year.

What makes medetomidine particularly dangerous is not just its presence in the drug supply, but what happens when people try to stop using it. Unlike opioid withdrawal, which is deeply unpleasant but rarely life-threatening in otherwise healthy adults, medetomidine withdrawal can escalate into a medical emergency requiring intensive care. The problem has already overwhelmed hospitals in major cities, signaling a shift in how addiction-related emergencies are being treated.

What Is Medetomidine and Why Is It in Fentanyl?

Medetomidine is a potent alpha-2 adrenergic agonist, a class of drugs that slow heart rate and lower blood pressure. It is not approved for human use, though its chemical cousin, dexmedetomidine, is used in hospitals for procedural sedation. On the streets, it goes by several names, including "rhino tranq," "mede," or "dex".

The drug emerged as a direct successor to xylazine, another veterinary tranquilizer that became notorious in the fentanyl supply starting around 2022. As law enforcement efforts targeted xylazine, clandestine drug producers pivoted to alternatives. Forensic testing found that medetomidine in the illegal supply exists as racemic mixtures, a chemical composition that does not match any licensed pharmaceutical product, strongly suggesting that illegal laboratories are manufacturing the substance rather than diverting it from veterinary supplies.

The geographic clustering of medetomidine detections reveals where the crisis is most acute. In 2025, medetomidine in fentanyl dominated the Northeast, accounting for 52 percent of cases, followed by the Midwest at 31 percent and the South at 17 percent. Western states remain largely unaffected for now. Between July and December 2025, researchers monitoring 20 sentinel sites across the US found medetomidine in nearly 35 percent of opioid-positive samples, and of 995 drug product samples that tested positive for medetomidine in that period, 98 percent also contained fentanyl.

Why Does Medetomidine Cause Such Severe Withdrawal?

When someone uses medetomidine-laced fentanyl regularly and then stops, the consequences are far more serious than typical opioid withdrawal. Medetomidine is more powerful and longer-lasting than both clonidine and xylazine, and its withdrawal syndrome can become medically serious within hours.

Exposure to medetomidine can drive the heart rate as low as 32 beats per minute and cause a sharp drop in blood pressure, producing deep sedation that outlasts the opioid effect by a considerable margin. When withdrawal begins, the opposite happens: the heart races, blood pressure climbs to dangerous levels, and nausea and vomiting become uncontrollable. Symptoms can start within hours of the last use, peaking at 18 to 36 hours, and may include tremors, chest pain, and shifting levels of consciousness.

Documented complications from medetomidine withdrawal include non-ST elevation myocardial infarction, a type of heart attack, and posterior reversible encephalopathy syndrome, a serious brain condition that demands intensive care. Between September 2024 and January 2025, three Philadelphia hospital systems admitted 165 patients for fentanyl withdrawal complicated by severe autonomic dysfunction, a condition where the nervous system loses control over heart rate and blood pressure. Pittsburgh reported similar clusters from October 2024 to March 2025, with many patients needing dexmedetomidine infusions and ICU-level care.

In May 2024, a Chicago overdose cluster involving medetomidine in fentanyl resulted in at least 16 hospitalizations and one death, with fentanyl appearing in every single medetomidine-positive sample across confirmed, probable, and suspected cases.

How to Recognize and Respond to Medetomidine Intoxication and Withdrawal

• Bradycardia as a Warning Sign: Clinicians should use heart rate as a key indicator of medetomidine intoxication. A dangerously slow heart rate, or bradycardia, points to medetomidine poisoning and requires immediate medical attention.
• Tachycardia and Hypertension in Withdrawal: When someone is withdrawing from medetomidine, a rapid heart rate combined with high blood pressure suggests the dangerous withdrawal syndrome is underway and medical intervention is critical.
• Dedicated Drug Testing: Standard hospital rapid drug screens rarely cover medetomidine, so clinicians need to request dedicated testing when prolonged sedation does not respond to naloxone, the overdose reversal medication.
• Seek Medical Support Before Stopping: Anyone who suspects regular exposure to medetomidine in fentanyl and wants to stop should seek medical support before doing so, as withdrawal can escalate quickly and without warning.

A critical limitation of current overdose response is that naloxone, the medication that reverses opioid overdoses by restoring breathing, does nothing against medetomidine's sedative effect. Health authorities stress that naloxone should still be administered first, since fentanyl is almost always present alongside medetomidine. Responders should focus on breathing, not on whether the person wakes up.

Medetomidine test strips are now available to people who use drugs. Chemists at the UNC Street Drug Analysis Lab report they appear highly sensitive, potentially outperforming existing strips for fentanyl or xylazine. Poison control centers are available to both clinicians and the public at 1-800-222-1222 for guidance on managing suspected medetomidine exposure.

What Public Health Experts Say About the Medetomidine Threat

The medetomidine crisis prompted an extraordinary joint advisory from the Centers for Disease Control and Prevention (CDC) and the White House Office of National Drug Control Policy (ONDCP) on April 2, 2026. The warning is notable because the CDC issues Health Alert Network advisories on a near-monthly basis, but these have historically focused on infectious disease outbreaks. No previous Health Alert Network advisory has directly addressed the illegal drug supply.

The pattern underlying the medetomidine threat is familiar to public health experts. Each time enforcement successfully disrupts one adulterant, another takes its place, usually one that is less familiar, harder to test for, and brings unexpected complications. Wastewater testing found medetomidine every week in at least 14 states between October 2025 and January 2026, and eight of 20 sentinel monitoring sites recorded medetomidine in more than half of all opioid-positive samples during that same window.

The federal advisory signals that the medetomidine drug threat now requires a coordinated answer across multiple sectors. That means clinical readiness in hospitals, stronger laboratory capacity for drug testing, active harm reduction outreach to people who use drugs, and community awareness working together rather than separately.

For people struggling with addiction to fentanyl or other opioids, the emergence of medetomidine underscores the importance of seeking professional treatment before a crisis occurs. Same-day alcohol and drug treatment programs are available in many areas, allowing individuals to act during their critical window of motivation. Medical detox programs, which provide prescription medications, continuous monitoring, and compassionate care to manage withdrawal symptoms safely, are essential for anyone dependent on opioids or other substances. Insurance coverage for addiction treatment is widely available under the Affordable Care Act and mental health parity laws, making professional help more accessible than many people realize.